BP,s info . update ., page-53

aa
- When Sanofi acquired Genzyme in 2011 for US$20.1bn , in the following year (2012) it simply  ended its US$1.25 bn collaboration (contractual agreements) with Osiris, which back in 2008 Genzyme paid US$130 million upfront to Osiris for rights to its MSC platform.

The Osiris MSC technology was a very small part of the Genzyme applications/IP acquired by Sanofi. In my opinion only, unless you are in the space and FULLY understand the potential of MSC's , you are more likely to look for applications with short to medium term sales reach.

So MSB picking up Osiris's MSC platform and IP ( one analyst called it 'check-mate') for US$100mn  to compliment MSB potent MPC technology  was a case of good fortune and smart's.

The point to note from the Sanofi decision is that Big Pharma can make a call regardless of contractual obligations...which is why Teva's decision to proceed speaks volumes  for the MPC technology and particularly REVASCOR.  If you think that Teva did not speak to the worlds most eminent Cardioligists ( independant to the current investgators like Emmerson Perin at Texas Heart Insitute) before proceeding with P3 and elating Revascor to its Pipeline , then you underestimate Big Pharma.

GLTAH.